Tolrestat in the primary prevention of diabetic neuropathy

Diabetes Care

Volumn 18, Issue 4, 1995, Pages 536-541

  Giugliano, Dario ^a   Acampora, Rita ^b   Marfella, Raffaele ^b   Di Maro, Giosué ^b   De Rosa, Nicoletta ^b   Misso, Lucio ^b   Ceriello, Antonio ^b   Quatraro, Antonio ^b   D'Onofrio, Felice ^b  

^a NONE   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

TOLRESTAT;

ADULT; AGED; ARTICLE; AUTONOMIC NEUROPATHY; CARDIOVASCULAR REFLEX; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; RANDOMIZED CONTROLLED TRIAL; TENDON REFLEX; VAGUS REFLEX; VALSALVA MANEUVER; VIBRATION SENSE;

EID: 0028943426     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.18.4.536     Document Type: Article

References (20)

1. Johnson PC, Doll SC, Cromey DW: Pathogenesis of diabetic neuropathy. Ann Neurol 19:450-457, 1986
2. Pirart J: Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1:168-188, 1978
3. Harris M, Eastman R, Cowie C: Symptoms of sensory neuropathy in adults with NIDDM in the U.S. population. Diabetes Care 16:1446-1452, 1993
4. Ziegler D, Gries FA, Mühlen H, Rathmann W, Spüler M, Lessmann F, the DIACAN Multicenter Study Group: Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes centers. Diabete & Metab 19:143-151, 1993
5. Dyck PJ, Thomas PK, Asbury AK, Winegrad AI, Porte D (Eds.): Diabetic Neuropathy. Philadelphia, Saunders, 1987
6. Dvornik D, Porte D (Eds.): Aldose Redactase Inhibition: An Approach to the Prevention of Diabetic Complications. New York, Biomedical Information Corporation, 1987
7. Masson EA, Boulton AJM: Aldose reductase inhibitors in the treatment of diabetic neuropathy: a review of the rationale and clinical evidence. Drugs 39:190-202, 1990
8. Giugliano D, Marfella R, Quatraro A, De Rosa N, Salvatore T, Cozzolino D, Ceriello A, Torella R: Tolrestat for mild diabetic neuropathy: a 52-week, randomized, placebo-controlled trial. Ann Intern Med 118:7-11, 1993
9. Marfella R, Salvatore T, Giugliano D, Di Maro G, Guinta R, Torella R, Juchmes J, Scheen A, Lefebvre PJ: Detection of early sympathetic cardiovascular neuropathy by squatting test in NIDDM. Diabetes Care 17:149-151, 1994
10. Marfella R, Giugliano D, Di Maro G, Acampora R, Giunta R, D'Onofrio F: The squatting test: a useful tool to assess both parasympathetic and sympathetic involvement of the cardiovascular autonomic neuropathy in diabetes. Diabetes 43:607-612, 1994
11. Parati G, Casadei R, Groppelli A, Di Rienzo M, Mancia G: Comparison of finger and intra-anerial blood pressure monitoring at rest and during laboratory testing. Hypertension 13:647-655, 1989
12. Ewing DJ, Clarke BF: Diagnosis and management of diabetic autonomic neuropathy. Br Med J 285:916-918, 1982
13. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH: A multicenter study of the prevalence of diabetic peripheral neuropathy in the U.K. hospital clinic population. Diabetologia 36:150-154, 1993
14. The DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes. N Engl J Med 329:77-86, 1993
15. Ryder S, Sarokhan B, Shand DG, Mullane JF: Human safety profile of tolrestat: an aldose-reductase inhibitor. Drug Dev Res 11:131-143, 1987
16. Sima AAF, Greene DA, Brown MB, Hohman TC, Hicks D, Graepel GJ, Bochenek WJ, Beg M, Gonen B, The Tolrestat Study Group: Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. J Diabetic Complications 7:157-169, 1993
17. Bellavere F, Balzani I, De Masi G, Carraro M, Carenza P, Cobelli C, Thomaseth K: Power spectral analysis of heart rate variations improves assessment of diabetic cardiac autonomic neuropathy. Diabetes 41:633-640, 1992
18. Hoffman RP, Sinkey CA, Kienzle MG, Anderson EA: Muscle sympathetic nerve activity is reduced in IDDM before overt autonomic neuropathy. Diabetes 42:375-380, 1993
19. Kreiner G, Woltz M, Fasching P, Leitha T, Eldmayer A, Waldhausl W, Dudczak R: Relationship between adrenergic cardiac innervation and left ventricular function in patients with IDDM: a scintigraphic study (Abstract). Diabetes 42:101A, 1993
20. Keen H, Payan J, Allawi J, γ-Linolenic Acid Multicenter Trial Group: Treatment of diabetic neuropathy with γ-linolenic acid. Diabetes Care 16:8-15, 1993